Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab, reaches First Milestone in HuMax-TAC Agreement with Serono27 Feb 2006
Genmab, preliminary announcement of annual report16 Feb 2006
Genmab, Announces Year End 2005 Financial Results16 Feb 2006
Genmab, Licenses Angiogenesis Targets from Bionomics13 Feb 2006
Genmab, articles of association dated 26 January 20061 Feb 2006
Genmab, Financial Calendar 200631 Jan 2006
Genmab, Announcement of Prospectus, Genmab Announces the Placing of its Private Placement27 Jan 2006
Genmab, Announces Over-Allotment Option Fully Exercised
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
27 Jan 2006
Genmab, announcement of prospectus12 Jan 2006
InvestorService: Genmab, Appoints Annarie Lyles as Head of Business Development3 Jan 2006
Genmab, HuMax-EGFr Awarded Fast Track Status from FDA3 Jan 2006
Genmab, articles of association as per 13 December 200514 Dec 2005
  • Previous
  • 1
  • More pages
  • 129
  • 130
  • 131
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863